Bevacizumab gamma (Lytenava®). HTA ID: 25043

Assessment Status Rapid Review Complete
HTA ID 25043
Drug Bevacizumab gamma
Brand Lytenava®
Indication Bevacizumab gamma (Lytenava®) is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration.
Assessment Process
Rapid review commissioned 03/07/2025
Rapid review completed 30/07/2025
Rapid review outcome A full HTA is not recommended. The NCPE recommends that bevacizumab gamma not be considered for reimbursement at the submitted price.

This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Further information on this process may be found here.

Further information on the status of this decision may be found here.